{"id":45754,"date":"2022-07-01T17:02:07","date_gmt":"2022-07-01T15:02:07","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/proassurance-second-quarter-2022-results-release-and-teleconference\/"},"modified":"2022-07-01T17:02:07","modified_gmt":"2022-07-01T15:02:07","slug":"proassurance-second-quarter-2022-results-release-and-teleconference","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/proassurance-second-quarter-2022-results-release-and-teleconference\/","title":{"rendered":"ProAssurance Second Quarter 2022 Results Release and Teleconference"},"content":{"rendered":"
\n

BIRMINGHAM, Ala.–(BUSINESS WIRE)–ProAssurance Corporation (NYSE:PRA<\/a>) will report results for the quarter ended June 30, 2022 after the close of normal New York Stock Exchange<\/a> trading on Monday, August 8, 2022.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nProAssurance will conduct a conference call at 10:00 AM ET on Tuesday, August 9, 2022 to discuss the results and other items of interest to investors participating in the call. US-based investors are invited to participate by phone by dialing either (844) 200-6205 (toll free) or (646) 904-5544 (local), and international investors may dial +1 (929) 526-1599. The access code for all attendees is 466956. The conference call will also be webcast at https:\/\/events.q4inc.com\/attendee\/617855902<\/a>.\n<\/p>\n

\nA telephone replay of the call will be available through at least Tuesday, August 16, 2022. US-based investors my access the replay by dialing (866) 813-9403 (toll free) or (929) 458-6194, and international investors may dial +44 (204) 525-0658. The access code for all attendees is 406681. A replay will be available through at least August 9, 2023 at ProAssurance.com<\/a>.\n<\/p>\n

\nAbout ProAssurance<\/b>\n<\/p>\n

\nProAssurance Corporation<\/a> is an industry-leading specialty insurer with extensive expertise in healthcare professional liability, products liability for medical technology and life sciences, legal professional liability, and workers\u2019 compensation insurance. ProAssurance Group is rated \u201cA\u201d (Excellent) by AM Best<\/a>; NORCAL Group is rated \u201cA-\u201d (Excellent) by AM Best<\/a>. ProAssurance and its operating subsidiaries are rated \u201cA-\u201d (Strong) by Fitch Ratings<\/a>.\n<\/p>\n

\nFor the latest on ProAssurance and its industry-leading suite of products and services, cutting-edge risk management and practice enhancement programs, follow @ProAssurance on Twitter<\/a> or LinkedIn<\/a>. ProAssurance\u2019s YouTube<\/a> channel regularly presents thought provoking, insightful videos that communicate effective practice management, patient safety and risk management strategies.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nJason Gingerich, VP, Investor Relations
\n
800-282-6242 \u2022 512-879-5101 \u2022 JasonGingerich@ProAssurance.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BIRMINGHAM, Ala.–(BUSINESS WIRE)–ProAssurance Corporation (NYSE:PRA) will report results for the quarter ended June 30, 2022 after the close of normal New York Stock Exchange trading on Monday, August 8, 2022. ProAssurance will conduct a conference call at 10:00 AM ET on Tuesday, August 9, 2022 to discuss the results and other items of interest to … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["entry","post","publish","author-business","post-45754","format-standard","category-industry"],"yoast_head":"\nProAssurance Second Quarter 2022 Results Release and Teleconference - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/proassurance-second-quarter-2022-results-release-and-teleconference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ProAssurance Second Quarter 2022 Results Release and Teleconference - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BIRMINGHAM, Ala.–(BUSINESS WIRE)–ProAssurance Corporation (NYSE:PRA) will report results for the quarter ended June 30, 2022 after the close of normal New York Stock Exchange trading on Monday, August 8, 2022. ProAssurance will conduct a conference call at 10:00 AM ET on Tuesday, August 9, 2022 to discuss the results and other items of interest to ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/proassurance-second-quarter-2022-results-release-and-teleconference\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-01T15:02:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220701005039\/en\/1502348\/21\/ProAssurance_Second_Quarter_2022_Results_Release_and_Teleconference.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/proassurance-second-quarter-2022-results-release-and-teleconference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/proassurance-second-quarter-2022-results-release-and-teleconference\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"ProAssurance Second Quarter 2022 Results Release and Teleconference\",\"datePublished\":\"2022-07-01T15:02:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/proassurance-second-quarter-2022-results-release-and-teleconference\\\/\"},\"wordCount\":281,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/proassurance-second-quarter-2022-results-release-and-teleconference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220701005039\\\/en\\\/1502348\\\/21\\\/ProAssurance_Second_Quarter_2022_Results_Release_and_Teleconference.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/proassurance-second-quarter-2022-results-release-and-teleconference\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/proassurance-second-quarter-2022-results-release-and-teleconference\\\/\",\"name\":\"ProAssurance Second Quarter 2022 Results Release and Teleconference - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/proassurance-second-quarter-2022-results-release-and-teleconference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/proassurance-second-quarter-2022-results-release-and-teleconference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220701005039\\\/en\\\/1502348\\\/21\\\/ProAssurance_Second_Quarter_2022_Results_Release_and_Teleconference.jpg\",\"datePublished\":\"2022-07-01T15:02:07+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/proassurance-second-quarter-2022-results-release-and-teleconference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/proassurance-second-quarter-2022-results-release-and-teleconference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/proassurance-second-quarter-2022-results-release-and-teleconference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220701005039\\\/en\\\/1502348\\\/21\\\/ProAssurance_Second_Quarter_2022_Results_Release_and_Teleconference.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220701005039\\\/en\\\/1502348\\\/21\\\/ProAssurance_Second_Quarter_2022_Results_Release_and_Teleconference.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/proassurance-second-quarter-2022-results-release-and-teleconference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ProAssurance Second Quarter 2022 Results Release and Teleconference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ProAssurance Second Quarter 2022 Results Release and Teleconference - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/proassurance-second-quarter-2022-results-release-and-teleconference\/","og_locale":"en_US","og_type":"article","og_title":"ProAssurance Second Quarter 2022 Results Release and Teleconference - Pharma Trend","og_description":"BIRMINGHAM, Ala.–(BUSINESS WIRE)–ProAssurance Corporation (NYSE:PRA) will report results for the quarter ended June 30, 2022 after the close of normal New York Stock Exchange trading on Monday, August 8, 2022. ProAssurance will conduct a conference call at 10:00 AM ET on Tuesday, August 9, 2022 to discuss the results and other items of interest to ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/proassurance-second-quarter-2022-results-release-and-teleconference\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-01T15:02:07+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220701005039\/en\/1502348\/21\/ProAssurance_Second_Quarter_2022_Results_Release_and_Teleconference.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/proassurance-second-quarter-2022-results-release-and-teleconference\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/proassurance-second-quarter-2022-results-release-and-teleconference\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"ProAssurance Second Quarter 2022 Results Release and Teleconference","datePublished":"2022-07-01T15:02:07+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/proassurance-second-quarter-2022-results-release-and-teleconference\/"},"wordCount":281,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/proassurance-second-quarter-2022-results-release-and-teleconference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220701005039\/en\/1502348\/21\/ProAssurance_Second_Quarter_2022_Results_Release_and_Teleconference.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/proassurance-second-quarter-2022-results-release-and-teleconference\/","url":"https:\/\/pharma-trend.com\/en\/proassurance-second-quarter-2022-results-release-and-teleconference\/","name":"ProAssurance Second Quarter 2022 Results Release and Teleconference - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/proassurance-second-quarter-2022-results-release-and-teleconference\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/proassurance-second-quarter-2022-results-release-and-teleconference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220701005039\/en\/1502348\/21\/ProAssurance_Second_Quarter_2022_Results_Release_and_Teleconference.jpg","datePublished":"2022-07-01T15:02:07+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/proassurance-second-quarter-2022-results-release-and-teleconference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/proassurance-second-quarter-2022-results-release-and-teleconference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/proassurance-second-quarter-2022-results-release-and-teleconference\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220701005039\/en\/1502348\/21\/ProAssurance_Second_Quarter_2022_Results_Release_and_Teleconference.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220701005039\/en\/1502348\/21\/ProAssurance_Second_Quarter_2022_Results_Release_and_Teleconference.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/proassurance-second-quarter-2022-results-release-and-teleconference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"ProAssurance Second Quarter 2022 Results Release and Teleconference"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45754","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=45754"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45754\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=45754"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=45754"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=45754"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}